Catabasis Pharmaceuticals

This article has multiple issues. Please help or discuss these issues on the . (Learn how and when to remove these template messages) This article has an unclear citation style. The references used may be made clearer with a different or consistent style of citation and footnoting. (August 2013) (Learn how and when to remove this template message) This article relies largely or entirely on a single source. Please help by introducing citations to additional sources. Find sources:  –  ·  ·  · scholar · JSTOR (November 2019) (Learn how and when to remove this template message)

Catabasis Pharmaceuticals

Type	Public
Traded as	Nasdaq: CATB Russell Microcap Index component
Industry	Pharmaceuticals
Headquarters	Cambridge, Massachusetts
Key people	Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer)
Products	Orally-delivered pharmaceuticals
Number of employees	24 (March 2019)
Website	www.catabasis.com

Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.^[1] At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.

In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values [1].

References[]